Clinical trials: Progressive Ophthalmoplegia
Progressive Supranuclear Palsy
Quality of Life of the Patient and the Burden of the Caregiver in Progressive Supranuclear Palsy
Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease from the parkinsonian syndrome group. PSP is characterised by the association of a non-doparesponsive parkinsonian syndrome with axial signs.
- Trial name
- Qual-PSP (NCT03638505)
- Testing
- PSP-QoL
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Progressive Supranuclear Palsy, Multi-System Atrophy
2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism
The PET tracer [F18]-FDDNP has a specific affinity for lesions containing tau protein. The study consists of two phases: In the first (cross-sectional) phase it will be assessed the uptake of [18F]-FDDNP in 10 cases with…
- Conditions
- Progressive Supranuclear Palsy, Multi-System Atrophy, Parkinsonism
- Trial name
- [F18]-FDDNP (NCT02214862)
- Testing
- [F18]-FDDNP
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP)
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
The overall goal of this imaging trial is to characterize [18F]MNI-815, a PET radioligand for imaging Tau.
- Conditions
- Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Cortical Basal Syndrome (CBS), Frontal Temporal Dementia (FTD)
- Trial name
- NCT02531360
- Testing
- [18F]MNI-815 (MNI-815)
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Parkinsonian Syndromes, Parkinson's Disease
Biomarkers in Parkinsonian Syndromes
Parkinson disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are neurodegenerative disorders. PD and MSA are alpha-synucleinopathies, which are characterized by the abnormal accumulation of…
- Conditions
- Parkinsonian Syndromes, Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- BIOPARK (NCT02114242)
- Testing
- CSF, blood and urine sampling, clinical measures of disease severity and progression
- Where
- 3 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson's Disease (PD), Parkinsonism
Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)
This study is designed to determine if magnetic resonance imaging (MRI) measures can be used to diagnose and monitor the progression of Parkinson's disease (PD) while distinguishing between PD and parkinsonisms [conditions that…
- Conditions
- Parkinson's Disease (PD), Parkinsonism, Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA)
- Trial name
- NCT01888185
- Where
- United States
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS)
4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2
The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug…
- Conditions
- Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD), Progressive Supranuclear Palsy (PSP)
- Trial name
- 4RTNI-2 (NCT02966145)
- Testing
- Observational Study
- Where
- 8 sites in United States, Canada
- Volunteers
- 293 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Progressive Supranuclear Palsy
A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP
A phase 2 study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 at different doses versus placebo on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy.
- Trial name
- NCT04008355
- Testing
- AZP2006 oral solution
- Where
- 3 sites in France
- Volunteers
- 36 people
- Sponsor
- AlzProtect SAS
Primary Parkinsonism, Secondary Vascular Parkinson Disease
Application of Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms
Based on a prospectively collected data analysis, a new tool, namely CoMDA (Cognition in Movement Disorders Assessment) is developed by merging each item of Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment…
- Conditions
- Primary Parkinsonism, Secondary Vascular Parkinson Disease, Multiple System Atrophy, Supranuclear Palsy, Progressive
- Trial name
- CoMDA-ML-P (NCT04858893)
- Testing
- CoMDA associated with Neural Net 91 classificator
- Where
- Italy
- Volunteers
- 562 people, healthy volunteers welcome
- Sponsor
- Ospedale Generale Di Zona Moriggia-Pelascini
Progressive Supranuclear Palsy
The MOTIVE-PSP Initiative (Progressive Supranuclear Palsy)
Progressive Supranuclear Palsy (PSP) is a rapidly progressive neurodegenerative disease characterized by falls and oculomotor disturbances.
- Trial name
- NCT04691635
- Testing
- evaluation of movements with sensors
- Where
- 3 sites in Italy
- Volunteers
- 165 people
- Sponsor
- University of Salerno
Progressive Supranuclear Palsy
Rehabilitation in Patients With Progressive Supranuclear Palsy
The investigators evaluate whether an aerobic, intensive, goal based and multidisciplinary rehabilitation treatment, previously conceived for Parkinson's disease, is effective for patients with progressive supranuclear palsy and…
- Trial name
- PSP-MIRTLoko (NCT02109393)
- Testing
- MIRT, MIRT+Lokomat
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Ospedale Generale Di Zona Moriggia-Pelascini
Progressive Supranuclear Palsy
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for…
- Trial name
- NCT06355531
- Testing
- FNP-223
- Where
- 44 sites in United States, France and 7 more
- Volunteers
- 241 people
- Sponsor
- Ferrer Internacional S.A.
Corticobasal Syndrome(CBS), Primary Progressive Aphasia(PPA)
Neuroinflammation in FTLD
The goal of this observational study is to investigate the role of neuroinflammation in frontotemporal lobar degeneration (FTLD). The main aims of this study are: 1.
- Conditions
- Corticobasal Syndrome(CBS), Primary Progressive Aphasia(PPA), Progressive Supranuclear Palsy(PSP), Behavioral Variant Frontotemporal Dementia (bvFTD)
- Trial name
- NCT06870838
- Testing
- 7T MRI scan, CSF, Blood withdrawal
- Where
- 2 sites in Netherlands
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Multiple System Atrophy, Progressive Supranuclear Palsy (PSP)
Synaptic Loss in Multiple System Atrophy
In this study the investigators would like to investigate the degree of damage of the synapses, an important part of the neurons vital for the communications between neurons, in Multiple System Atrophy (MSA), and pathology…
- Trial name
- NCT05121012
- Testing
- Study procedures for MSA patients, Study procedures for PSP patients
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- University of Exeter
Blepharoptosis, Ptosis, Eyelid
Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis
This clinical trial will evaluate two non-surgical devices designed to improve eye lid opening for patients with severe Blepharoptosis (incomplete opening of the eyelids).
- Conditions
- Blepharoptosis, Ptosis, Eyelid, Myasthenia Gravis, Stroke
- Trial name
- NCT04678115
- Testing
- Magnetic Levator Prosthesis (MLP), Kinesiotape Frontalis Sling (KTFS)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Progressive Supranuclear Palsy, Corticobasal Degeneration
A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration
The goal of this trial is to evaluate the safety and tolerability of lithium in people with progressive supranuclear palsy or corticobasal degeneration.
- Trial name
- NCT00703677
- Testing
- Lithium
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 17 people
- Sponsor
- Westat
Parkinson Disease, Essential Tremor
Brain Network Activation in Patients With Movement Disorders
The diagnosis and management of movement disorders, such as Parkinson's disease (PD), parkinson-plus syndromes (PPS), dystonia, essential tremor (ET), normal pressure hydrocephalus (NPH) and others is challenging given the lack…
- Conditions
- Parkinson Disease, Essential Tremor, Dystonia, Normal Pressure Hydrocephalus
- Trial name
- BNA-MDi (NCT03269201)
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Sheba Medical Center
Parkinson's Disease, Parkinsonism
Modifiable Variables in Parkinsonism (MVP)
We are trying to identify factors associated with improved quality of life and fewer PD symptoms. We are attempting to identify practices, beliefs, and therapies used by individuals who report excellent quality of life, few PD…
- Conditions
- Parkinson's Disease, Parkinsonism, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- NCT02194816
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Bastyr University
Progressive Supranuclear Palsy
Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks
This is a 12-week study of oral tolfenamic acid vs. placebo in Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT04253132
- Testing
- Tolfenamic Acid
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NeuroTau, Inc.
Mitochondrial Diseases
A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease
A long-term extension study to assess the safety, tolerability and efficacy of cysteamine bitartrate delayed-release capsules (RP103) in children with inherited mitochondrial diseases who previously enrolled into study…
- Trial name
- NCT02473445
- Testing
- Cysteamine Bitartrate
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Amgen